N4 Pharma

We are moving! To stay updated on our RNA pipeline and #Nuvec platform, please follow our official LinkedIn page for all future news and corporate updates. Follow us here: linkedin.com/company/1795973… Explore our new chapter: thaliatx.com/ $THAT #Biotech #LSE

N4 Pharma (AIM: N4P) appoints Dr David H Solomon as CEO and proposes rename to Thalia Therapeutics. Strategic focus on RNA therapeutics, launching a dual-acting siRNA programme in cardiovascular disease + advancing Nuvec®. Read the full RNS londonstockexchange.com/news… #Biotech #RNA

Don't miss our expert view in @ONdrugDelivery which explores how Nuvec® uses functionalised silica nanoparticles to deliver multiple cargos into the tumour microenvironment, including pancreatic and lung cancer models. Read more here: ondrugdelivery.com/improving… #N4P

The RNA therapeutics market is set to hit $18B by 2028, but manufacturing and delivery barriers remain. We spoke with @DrugTargetRev on how Nuvec® could overcome these. Want to know more? Read the interview here: drugtargetreview.com/article… #N4P #RNATherapeutics

Watch our update and review of 2025. Key milestones include strong in vivo data from our IBD programme, success with the University of Strathclyde and successful preclinical demonstrations and targeting of Nuvec®. Learn more: n4pharma.com/activity-update… #N4P

Discover the challenges and breakthroughs in RNA-based cancer therapies with our Head of R&D. In her video summary she explains why collaboration across fields is vital as complex delivery systems move closer to clinical use. Watch it here: n4pharma.com/activity-update… #N4P #Oncology

N4 Pharma plc has provided an update and review of 2025. Key highlights include success with the University of Strathclyde, successful preclinical demonstrations and targeting of Nuvec©, and a strengthening of our IP. Learn more in this video: n4pharma.com/s/697ded

#RNAtherapeutics offer precision in cancer treatment, but targeted delivery beyond the liver is challenging. Silica nanoparticle platforms like Nuvec® enable multi-target delivery to tumours and microenvironments. Learn more in @ONdrugDelivery: bit.ly/3MIELUq

What if RNA medicines could be guided directly to tumours, sparing healthy tissue? Targeted delivery is the next advance in RNA therapeutics. Our Head of R&D discusses this with @DrugTargetRev. Read more here: drugtargetreview.com/article… #N4P #RNAtherapeutics

During #CrohnsAndColitisAwarenessWeek, we spotlight the millions of people living with #IBD. These conditions cause chronic gut inflammation with symptoms that impact daily life. Join the conversation, raise awareness, and support those affected: crohnscolitisfoundation.org #N4101

ICYMI: Dive into the science and strategy behind Nuvec® and how it's shaping RNA therapeutics through our explainer video series hosted by @n4pharma CEO, Nigel Theobald: n4pharma.com/n4-pharma-educa… #RNAtherapeutics #Biotech #Nuvec #GeneTherapy #N4P

Nuvec® unlocks new RNA therapy possibilities for vaccines, gene silencing & oral treatments. Discover its potential for safe, targeted and efficient intercellular delivery here: n4pharma.com/activity-update… #RNA #Nanoparticle #Biotech #N4P

From research at Oxford to leading 80+ commercial deals, Dr. Simon Bennett, @n4pharma Commercial Director, brings deep expertise in biopharma growth and business strategy. Connect here: linkedin.com/in/simon-bennet… #MeetTheTeam #Biotech #Pharma

How can next-gen #RNA therapies better target diseases with precision and safety? Discover Nuvec®, our silica nanoparticle delivery platform. Unlike other methods, Nuvec® can load multiple RNA and DNA molecules and direct therapy to specific cells: n4pharma.com/activity-update… #N4P

DNA & RNA therapies have huge potential, but delivery remains a key hurdle: targeting the right tissue while avoiding immune responses. A new @Nature article shows non-viral vectors like nanoparticles are leading the way. Read more: nature.com/articles/d41573-0… #Nuvec #RNAtherapy #N4P

From the lab to commercialisation, Dr. Margaret Courtney brings 25+ years of CMC leadership to @n4pharma, advising biopharma partners on development strategy and manufacturing excellence. Connect with her here → linkedin.com/in/margaret-cou… #MeetTheTeam #DrugDevelopment #CMC #N4P

Heading to the 13th International mRNA Health Conference in Berlin? Meet our Commercial Director, Dr. Simon Bennett, to talk RNA delivery innovation: linkedin.com/in/simon-bennet… #mRNA #DrugDelivery #N4P @mrnaconference

Meet Dr. Mark Edbrooke, Head of Strategy at @n4pharma and an independent scientific consultant with 25 years in pharma R&D. He led genomics and nucleic acid teams at GSK and worked with Ionis and Moderna at AstraZeneca. Connect with Mark: linkedin.com/in/mark-edbrook… #N4P #RNA

How do successful biotech companies navigate investment and growth? Our new Case Studies page showcases stories from peers like @WaveLifeSci Sciences and DTx Pharma, offering real-world blueprints to guide our journey in RNA therapeutics: n4pharma.com/case-studies #N4P

The #siRNA drug market is set to grow over 6x by 2031, driven by advances in RNA therapies. At @n4pharma, Nuvec® enables delivery of multiple siRNAs in one particle which could be key to unlocking siRNA’s full potential in cancer & gene therapy. #DrugDelivery #Biotech